{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:21:01Z","timestamp":1782145261406,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinthera.2022.08.005","type":"journal-article","created":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T16:45:28Z","timestamp":1663433128000},"page":"1297-1309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population"],"prefix":"10.1016","volume":"44","author":[{"given":"Sajid","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani Mohamed","family":"Sabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsin Sohail","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia Al","family":"Tikriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.08.005_bib0001","first-page":"511","article-title":"PCSK9 inhibitors and cardiovascular disease: Heralding a new therapeutic era. Vol. 26, Current Opinion in Lipidology","author":"Chapman","year":"2015","journal-title":"Lippincott Williams and Wilkins"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0002","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"29","key":"10.1016\/j.clinthera.2022.08.005_bib0003","doi-asserted-by":"crossref","first-page":"ehw480","DOI":"10.1093\/eurheartj\/ehw480","article-title":"European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk","volume":"38","author":"Landmesser","year":"2016","journal-title":"European Heart Journal [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0004","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Arnett","year":"2019","journal-title":"Circulation. NLM (Medline)"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"European Heart Journal [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0006","unstructured":"FDA. REPATHA (evolocumab) injection, for subcutaneous use. [cited 2021 Dec 30]; Available from: www.fda.gov\/medwatch."},{"key":"10.1016\/j.clinthera.2022.08.005_bib0007","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0008","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors [Internet]","author":"Dadu","year":"2014","journal-title":"Nature Reviews Cardiology"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0009","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1373\/clinchem.2007.091280","article-title":"Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol","volume":"53","author":"Alborn","year":"2007","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0010","first-page":"71","article-title":"Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres","author":"Kohli","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0011","first-page":"1","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Medicine [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0012","unstructured":"Kane SP. ASCVD risk calculator: 10-year risk of first cardiovascular event using pooled cohort equations-ClinCalc.com [Internet]. [cited 2021 Mar 21]. Available from: https:\/\/clincalc.com\/Cardiology\/ASCVD\/PooledCohort.aspx"},{"issue":"7","key":"10.1016\/j.clinthera.2022.08.005_bib0013","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1474515119856207","volume":"18","author":"Rossello","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"issue":"2","key":"10.1016\/j.clinthera.2022.08.005_bib0014","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1373\/clinchem.2017.279422","article-title":"Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe","volume":"64","author":"Ruel","year":"2018","journal-title":"Clinical chemistry"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0015","unstructured":"Dutch Criteria for Familial Hypercholesterolemia (FH)-MDCalc [Internet]. [cited 2021 Jul 1]. Available from: https:\/\/www.mdcalc.com\/dutch-criteria-familial-hypercholesterolemia-fh"},{"issue":"Supplement_1","key":"10.1016\/j.clinthera.2022.08.005_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.2582","article-title":"Effectiveness, adherence and safety of evolocumab in a Swiss multicenter prospective observational study","volume":"42","author":"Nanchen","year":"2021","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.clinthera.2022.08.005_bib0017","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK9 inhibitors: a real-world experience","volume":"105","author":"G\u00fcrg\u00f6ze","year":"2019","journal-title":"Clinical Pharmacology and Therapeutics [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0018","first-page":"287","article-title":"Pcsk9-inhibition in routine clinical practice: real world data from Germany","author":"Waldmann","year":"2019","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.clinthera.2022.08.005_bib0019","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1177\/2047487319868792","article-title":"HeFH in real life, how to: more evolocumab than authorized","volume":"27","author":"Sbrana","year":"2020","journal-title":"European Journal of Preventive Cardiology [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0020","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.clinthera.2017.02.011","article-title":"Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain","volume":"39","author":"Villa","year":"2017","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0021","doi-asserted-by":"crossref","unstructured":"Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, et\u00a0al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. https:\/\/doi.org\/101080\/1369699820171284078 [Internet]. 2017 Jun 3 [cited 2021 Sep 13];20(6):555\u201364.","DOI":"10.1080\/13696998.2017.1284078"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0022","doi-asserted-by":"crossref","unstructured":"Kr\u00e4henb\u00fchl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won't do! Drugs 2016 76:12 [Internet]. 2016 Jul 25 [cited 2021 Sep 13];76(12):1175\u201390. Available from: https:\/\/link.springer.com\/article\/10.1007\/s40265-016-0613-0","DOI":"10.1007\/s40265-016-0613-0"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0023","doi-asserted-by":"crossref","unstructured":"Alberts MJ, Thompson PD. PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibition and stroke prevention. Stroke [Internet]. 2020 [cited 2021 Sep 6];1361\u20132. Available from: https:\/\/www.ahajournals.org\/doi\/abs\/10.1161\/STROKEAHA.120.028567","DOI":"10.1161\/STROKEAHA.120.028567"},{"issue":"5","key":"10.1016\/j.clinthera.2022.08.005_bib0024","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/1074248418774043","article-title":"Comparison of LDL-C reduction using different evolocumab doses and intervals: biological insights and treatment implications","volume":"23","author":"Wasserman","year":"2018","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics [Internet]"},{"issue":"22","key":"10.1016\/j.clinthera.2022.08.005_bib0025","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA [Internet]"},{"issue":"1","key":"10.1016\/j.clinthera.2022.08.005_bib0026","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0300060518800595","article-title":"Real-world use of PCSK9 inhibitors: A single-center experience","volume":"47","author":"Sarsam","year":"2019","journal-title":"Journal of International Medical Research"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0027","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0028","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol [Internet]"},{"issue":"5","key":"10.1016\/j.clinthera.2022.08.005_bib0029","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/clc.23600","article-title":"Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab","volume":"44","author":"Desai","year":"2021","journal-title":"Clinical cardiology"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0030","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2147\/DDDT.S114091","article-title":"Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up [Internet]","author":"Dixon","year":"2017","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0031","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"15","key":"10.1016\/j.clinthera.2022.08.005_bib0032","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA [Internet]"},{"key":"10.1016\/j.clinthera.2022.08.005_bib0033","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiology [Internet]"},{"issue":"1","key":"10.1016\/j.clinthera.2022.08.005_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21873\/invivo.12232","article-title":"PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance","volume":"35","author":"Voutyritsa","year":"2021","journal-title":"in vivo"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:58:22Z","timestamp":1758963502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0149291822002855"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}